Treatment
- abiraterone
- anastrozole
- bicalutamide
- capecitabine
- CAPOX
- carboplatin
- cetuximab
- cisplatin
- crizotinib
- dacarbazine
- docetaxel
- doxorubicin
- epirubicin
- erlotinib
- everolimus
- exemestane
- fluorouracil
- flutamide
- FOLFOX
- FOLFIRI
- fulvestrant
- gefitinib
- gemcitabine
- goserelin
- imatinib
- irinotecan
- lapatinib
- letrozole
- leuprolide
- liposomal doxorubicin
- megestrol acetate
- nab-paclitaxel
- oxaliplatin
- paclitaxel
- panitumumab
- pemetrexed
- pertuzumab
- sorafenib
- sunitinib
- tamoxifen
- temozolomide
- temsirolimus
- topotecan
- toremifene
- trastuzumab
- vemurafenib
megestrol acetate
Megestrol acetate modifies the action of other steroid hormone receptors and thereby
exerts a direct cytotoxic effect on tumor cells. Pharmacologic doses of megestrol
acetate not only decrease the number of hormone-dependent human breast cancer
cells, but are also capable of modifying and abolishing the stimulatory effects of estrogen
on these cells. It has been suggested that progestins may inhibit in one of two ways: by
interfering with the stability, availability, or turnover of the estrogen receptor complex in
its interaction with genes or, in conjunction with the progestin receptor complex, by
interacting directly with the genome to turn off specific estrogen-responsive genes.
Megestrol acetate is indicated* for treatment of breast cancer or endometrial carcinoma.
*Please refer to full prescribing information/package insert for precise indications.
